Amelia Crawford, PA
Physician Assistant · Easley, SCNPI 1396002150
Payments from drug & device makers
Across 88 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$302
- Smith+Nephew$141
- GSK$139
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$128
- Johnson & Johnson$122
- Amgen$73
- plus $430 from 13 others
What the payments were for
- Food & beverage$1,335100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $302 |
| Smith+Nephew | 1 | $141 |
| GSK | 8 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $128 |
| Johnson & Johnson | 12 | $122 |
| Amgen | 5 | $73 |
| AbbVie | 5 | $72 |
| Lilly USA, LLC | 4 | $55 |
| Boehringer Ingelheim | 3 | $54 |
| AstraZeneca | 3 | $46 |
| Astellas Pharma US Inc | 3 | $36 |
| Abbott | 2 | $30 |
| Dexcom, Inc. | 2 | $27 |
| Bayer | 2 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Exact Sciences | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REAL INTELLIGENCE$141
- Journey II$141
- Tandem$141
How this compares
$1,335 in reported general payments places this provider in the 70th percentile of 1,852 physician assistant providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 55 | $60,792 |
| OzempicSemaglutide | 37 | $58,885 |
| JardianceEmpagliflozin | 39 | $52,237 |
| FarxigaDapagliflozin Propanediol | 20 | $25,873 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $21,683 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $17,861 |
| EliquisApixaban | 11 | $14,387 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $13,339 |
| XareltoRivaroxaban | 12 | $13,131 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $12,543 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $12,219 |
| LinzessLinaclotide | 12 | $10,432 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,535 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,207 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $4,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $54 | $64,78151 claims |
| Lilly USA, LLCMounjaro | $55 | $60,79255 claims |
| Novo NordiskOzempic | $302 | $58,88537 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $139 | $32,60248 claims |
| AstraZenecaFarxiga | $46 | $25,87320 claims |
| PfizerEliquis | $14 | $14,38711 claims |
| Johnson & JohnsonXarelto | $122 | $13,13112 claims |
| AbbVieLinzess, Synthroid | $72 | $12,68356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,852 physician assistant providers in South Carolina.
Other physician assistant in Easley
- Benjamin AddyWest Columbia$377K
- Michael OvercashCharleston$210K
- Allison LesterMt Pleasant$163K
- Nicole KeeterFort Mill$129K
- William YoungGreenville$117K
- Stephanie DavisAnderson$78K
- Vicki RobertsWest Columbia$77K
- Eric ShoupColumbia$74K
- Lauren OlsonNorth Charleston$62K
- Martha GreenSummerville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.